112P - Role of EGFR mutational status in response to first-line classical chemotherapy in patients with non-small-cell lung cancer
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
I. Franco1, A. Antunes1, S. Campainha1, S. Conde2, A.M. Barroso3
Several studies showed that EGFR mutation is a predictor of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment response in patients with non-small-cell lung cancer (NSCLC). However, to what extent EGFR mutation status may influence the response to first-line chemotherapy regimens other than EGFR-TKI is not known. First-line treatment with EGFR-TKI was approved in Portugal in 2012. In our center, EGFR mutation analysis is performed to all NSCLC patients since 2006. The aim of this study was to evaluate the response to first-line classical chemotherapy – disease control, progression free survival (PFS) and overall survival (OS) – according to EGFR mutational status.